UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): April 1, 2020

 

INNOVATION PHARMACEUTICALS INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada

 

001-37357

 

30-0565645

(State or Other Jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

File Number)

 

Identification No.)

 

301 Edgewater Place - Suite 100

Wakefield, Massachusetts

 

01880

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (978) 921-4125

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Exchange Act: none

 

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

 

 

Item 7.01. Regulation FD Disclosure

 

On April 1, 2020, Innovation Pharmaceuticals Inc. issued a press release titled, Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19.

 

A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the accompanying press release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

Description

99.1

 

Press release dated April 1, 2020

  

 
2

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INNOVATION PHARMACEUTICALS INC.
        
Dated: April 1, 2020 By: /s/ Leo Ehrlich

 

Name:

Leo Ehrlich  
  Title: Chief Executive Officer  

  

 
3

 

Innovation Pharmaceuticals (QB) (USOTC:IPIX)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Innovation Pharmaceuticals (QB) Charts.
Innovation Pharmaceuticals (QB) (USOTC:IPIX)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Innovation Pharmaceuticals (QB) Charts.